A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma

Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas

NCT04407741 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

NCT05572983 ·Status: RECRUITING ·Phase: PHASE2

Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

NCT04480099 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients

NCT01788137 ·Status: UNKNOWN ·Phase: PHASE3

A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients

NCT06255704 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)

NCT06750991 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

NCT03631862 ·Status: UNKNOWN ·Phase: PHASE4

Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years

NCT05429918 ·Status: UNKNOWN

Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

NCT05498259 ·Status: UNKNOWN ·Phase: PHASE2

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

NCT04660799 ·Status: COMPLETED ·Phase: PHASE2

Go-CHOP as the Frontline Therapy for PTCL

NCT05963347 ·Status: RECRUITING ·Phase: PHASE2

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

NCT03155425 ·Status: COMPLETED ·Phase: PHASE2

CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma

NCT01746992 ·Status: UNKNOWN ·Phase: PHASE4

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

NCT05821192 ·Status: UNKNOWN ·Phase: NA

A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma

NCT06104553 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

NCT04480125 ·Status: UNKNOWN ·Phase: PHASE2

A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL

NCT06573645 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

NCT06712173 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

NCT03952572 ·Status: UNKNOWN ·Phase: PHASE3

A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

NCT05040906 ·Status: UNKNOWN ·Phase: PHASE3

A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy

NCT05527912 ·Status: UNKNOWN ·Phase: PHASE2

A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas

NCT05113069 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1

Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

NCT04922567 ·Status: RECRUITING ·Phase: PHASE2

CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma

NCT00893516 ·Status: TERMINATED ·Phase: PHASE2

A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

NCT05051891 ·Status: COMPLETED ·Phase: PHASE3